While the reported $400 billion merger discussions between AstraZeneca and Bristol Myers Squibb never advanced, the fact that a combination of this scale was even rumored sent shock waves through the industry. That the deal may have been considered at all reflects the extraordinary strategic pressure now facing large pharmaceutical…
In the evolving pharmaceutical landscape of 2026, companies face unprecedented financial pressures on multiple fronts, including rising costs and shrinking opportunities for revenue generation. The Inflation Reduction Act (IRA), now in its fourth year, continues to compress peak sales windows for top-selling drugs through price negotiations. At the same time,…
Large pharmaceutical companies cut more than 22,000 jobs in 2025 as a $300 billion patent cliff approaches, signaling a broad industry correction in workforce size and cost structure ahead of significant revenue losses. These layoffs are not simply cost containment. They reflect deeper strategic recalibration, and companies must respond with…
When Congress passed the Inflation Reduction Act in 2022, most headlines focused on lower drug prices for Medicare beneficiaries. Far less attention has been paid to how compressing the product prime earning cycle is reshaping pharmaceutical development and commercialization strategy. Pharmaceutical leaders need an alternative approach to the blockbuster model…
After failing to obtain the needed votes required to include mandatory MFN legislation in his Big Beautiful Bill, President Trump has looked to other avenues to engage MFN pricing with the pharma industry, a position he signaled clearly in two Executive Orders in April and May 2025. Trump sent letters…
Artificial intelligence is rapidly becoming embedded across the pharmaceutical industry, from drug discovery to commercialization. Yet as adoption accelerates, many organizations remain unclear about where AI creates real value and where it simply adds complexity. Rather than treating AI as a set of isolated use cases, pharma leaders should approach…
